MAC Viva Glam supports HIV/AIDS fund campaign | Lifestyle.INQ

OCTOBER 27, 2022

Since 1994 every cent from the sales of MAC Viva Glam Lipstick and Lipglass has gone toward helping women, men and children living with and affected by HIV/AIDS.
The MAC AIDS Fund, the philanthropic arm of MAC Cosmetics launched in 1994, is a leader in the global fight against HIV and AIDS, supporting organizations in more than 96 countries and territories that are working to combat the epidemic and to improve the lives of people afflicted with HIV/AIDS.

Funded by the full sales of Viva Glam Lipstick and Lipglass, the campaign has raised more than $440 million.
As the largest corporate non-pharmaceutical HIV/AIDS funder, the MAC AIDS Fund strives to make a meaningful difference in the lives of people afflicted with HIV/AIDS.

It focuses on highlighting the link between poverty and AIDS, and strengthening services available to underserved populations.

The MAC family volunteers in local charities and in MAC stores worldwide that sell Viva Glam.

A pioneer in the campaign against HIV/AIDS, the MAC AIDS Fund has been a trailblazer for more than 20 years, funding groundbreaking and innovative programs and investing in regions and populations that are not often prioritized by other funders.

What can a purchase of one MAC Viva Glam lipstick provide?

One rapid oral HIV test, one pair of school shoes for a child orphaned by AIDS; one resident in an HIV/AIDS housing organization with a new job interview outfit; one week of fresh fruit, vegetables and grocery essentials to a mother and child affected by HIV; two nights in a clean, safe place for one resident living with HIV/AIDS; 10 individually tailored, nutritious meals for a person affected by HIV/AIDS; 14 HIV tests for pregnant mothers; 32 safer sex kits which include condoms, lubricant and instructions; 200 new syringes, which are given to injection drug users in exchange for used needles to prevent HIV infection; 254 condoms to prevent transmission of HIV.


The MAC Viva Glam, Lipglass will be available in April.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

MOST VIEWED STORIES

FROM THE NICHE TITLES